OR WAIT null SECS
San Bruno, CA. May 21, 2015. PRC Clinical, the Clinical Trial Management CRO, is officially joining the Alliance for Regenerative Medicine (ARM). The ARM counts more than 200 pioneering organizations, fostering research, development, investment, and commercialization of transformational treatments and cures for patients worldwide.
PRC Clinical, the California-based CRO focused in Clinical Trial Management, has developed a strong expertise in stem cell and regenerative research working with sponsors in the United States and Israel. “We believe regenerative medicine holds exciting potential to resolve unmet medical needs of untreatable diseases and possibly ease the burdens of an aging population” states Curtis Head, CEO at PRC Clinical. “Joining ARM is one more way for PRC to express our commitment to developing highly innovative therapies for the human condition and beyond.”
Regenerative Medicine is focused on the development and application of cell-based therapies and related technologies to enhance the natural healing process, and/or replace or regenerate organs and tissues. Delivering cures through regenerative medicine requires coordination amongst a broad range of stakeholder groups from industry, academia, government, healthcare professionals, the investment community and consumer advocates. ARM members include leading pharmaceutical companies such as Pfizer, Johnson & Johnson and Novartis, as well as innovative life science companies, research institutions, capital providers, foundations, associations, and patient advocates.
PRC Clinical will attend ARM’s 2015 Stem Cell Meeting on the Mesa on October 7-9 2015 in La Jolla, California. This annual meeting attracts more than 800 industry-leading professionals for partnering opportunities, interactive panels, and scientific lectures.